Xcout Intel
BioTime competitors & alternatives
The 12 closest competitors and alternatives to BioTime among biotechnology companies — ranked by similarity to what BioTime actually does, not by market-cap band.
Subscribe to see BioTime’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BioTime
BioTime, Inc. was a U.S. biotechnology company focused on developing regenerative-medicine and cell-based therapies for serious medical conditions. In 2019, it changed its name to Lineage Cell Therapeutics, which continues developing cell therapies for patients with conditions including spinal cord injury, retinal disease, and cancer.
BioTime at a glance
BioTime is a biotechnology company headquartered in United States. It has raised at least $18M across the 2 funding rounds on record. Its most recent funding round raised $10M in August 2017. Xcout tracks 2 named people at BioTime, including Lachman Lund (Dpharm, Bcom).
BioTime leadership
- Lachman LundDpharm, Bcom
- Nitesh LuandBpharm, MS
BioTime funding rounds
At least $18M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $10M | 1 named | |
| — | $8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 BioTime competitors
Ranked by semantic similarity — how close each company is to BioTime by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Similar biotechnology company
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Similar biotechnology company
Cell Research Corporation is a biotechnology company specializing in umbilical cord lining stem cell technology and banking. The company provides products, services, and contract research related to stem cell applications for wound healing, regenerative medicine, and cosmeceuticals.
Similar biotechnology company
CBMG Holdings, formerly known as Cellular Biomedicine Group, is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies for cancers and stem cell therapies. The company focuses on immune cell therapies and T cell-based therapeutics. It has subsequently announced a name change to AbelZeta Pharma, Inc.
Biotech
CiRC Biosciences is a privately held regenerative medicine and cell therapy company founded in 2019 and based in Chicago, Illinois, focused on developing cellular reprogramming solutions for degenerative diseases.
Similar biotechnology company
Link Cell Therapies Inc. is a platform biotechnology company maintaining its headquarters in South San Francisco, California. The company develops novel agents targeting hematologic and related diseases.
Biotech
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Similar biotechnology company
Lin BioScience is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class drug candidates for the treatment of cancer, eye diseases, and metabolic diseases. The company serves patients with significant unmet medical needs through targeted therapies such as oral treatments for dry age-related macular degeneration, Stargardt disease, and acute leukemia.
Biotech
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Biotech
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Biotech
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Similar biotechnology company
LifeCyte Innovations is a clinical-stage biopharmaceutical company that develops novel oral therapies targeting chronic inflammation to slow the progression of age-related degenerative conditions. Its primary product offering, RestoViz, is an investigational oral combination therapy designed to treat age-related macular degeneration (AMD) by reducing inflammation, oxidative stress, and drusen buildup, with additional clinical studies evaluating applications for mild cognitive impairment, Alzheimer's disease, and traumatic brain injury.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BioTime and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BioTimeand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →